Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method
Sponsor: Ipsen
Listed as NCT00234533, this PHASE3 trial focuses on Dwarfism and Pituitary Diseases and remains completed. Sponsored by Ipsen, it has been updated 11 times since 2004, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Feb 2019 — Jan 2020 [monthly]
Completed PHASE3
-
Nov 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Sep 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Angers, France , Athens, Greece , Barcelona, Spain , Bordeaux, France , Bratislava, Slovakia , Brussels, Belgium , Bucharest, Romania , Cardiff, United Kingdom , Catania, Italy and 29 more locations